EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Evolution of AChE Inhibitors in Alzheimer's Disease: From Single‐Target to Multi‐Target Ligands

Namrashee V Mehta, Akshay Kapadia, Mihir Khambete iD, Arundhati Abhyankar iD

ChemBioChem · 15.09.2025 · 26 (17)

DOI: 10.1002/cbic.202500053 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemBioChem, online erschienen am 28.07.2025. Verfasst von Namrashee V Mehta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Program in Chemical Biology, University of Michigan, Ann Arbor, Michigan, 48108, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cholinesterase Inhibitors, Acetylcholinesterase. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 278 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a chronic neurodegenerative disease marked by cognitive decline, neuronal degeneration, and the accumulation of intracellular neurofibrillary tangles, extracellular amyloid plaques, and neuroinflammation. Current treatment strategies, such as acetylcholinesterase inhibitors (AChEIs) and N‐methyl‐D‐aspartate receptor antagonists, offer symptomatic relief but fail to stop disease progression. The development of multi‐target‐directed ligands (MTDLs) has gained attention as a method to address the complex pathology of AD. This review provides a detailed account of the journey of AChE inhibitors from single‐target ligands to MTDLs, emphasizing the structural changes that improve target specificity, blood–brain barrier penetration, and therapeutic impact. By exploring these advancements, the review highlights the potential of MTDLs to overcome the limitations of traditional single‐target approaches and contribute to the discovery of more effective anti‐Alzheimer therapies along with discussing potential pitfalls.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCholinesterase InhibitorsAcetylcholinesteraseHumansLigandsBlood-Brain BarrierAnimals

Stichwörter der Autor:innen

AChEAlzheimer's diseaseBuChEdrug discoverymulti‐target directed ligands

Substanzen

Cholinesterase InhibitorsLigandsAcetylcholinesterase

Autor:innen und Institutionen

  • Program in Chemical Biology, University of Michigan, Ann Arbor, Michigan, 48108, USA.
  • Donders Centre for Neuroscience - Neurobiology, Radboud University, Houtlaan 4, 6525 XZ, Nijmegen, Netherlands.
  • Department of Chemistry, Yale University, New Haven, Connecticut, 06511, USA.
  • Department of Pharmaceutical Chemistry, Quality Assurance, and Pharmaceutical Analysis, SVKMs Dr. Bhanuben Nanavati College of Pharmacy, Vaikunthlal Mehta Rd, Vile Parle West, Mumbai, Maharashtra, 400056, India.

ORCID-Profile: Mihir Khambete, Arundhati Abhyankar

Zitieren

APA

Mehta, N. V., Kapadia, A., Khambete, M., & Abhyankar, A. (2025). The Evolution of AChE Inhibitors in Alzheimer's Disease: From Single‐Target to Multi‐Target Ligands. ChemBioChem, 26(17). https://doi.org/10.1002/cbic.202500053

Vancouver

Mehta NV, Kapadia A, Khambete M, Abhyankar A. The Evolution of AChE Inhibitors in Alzheimer's Disease: From Single‐Target to Multi‐Target Ligands. ChemBioChem. 2025;26(17). doi:10.1002/cbic.202500053

BibTeX
@article{Mehta2025,
  author = {Mehta, Namrashee V and Kapadia, Akshay and Khambete, Mihir and Abhyankar, Arundhati},
  title = {The Evolution of AChE Inhibitors in Alzheimer's Disease: From Single‐Target to Multi‐Target Ligands},
  journal = {ChemBioChem},
  year = {2025},
  volume = {26},
  number = {17},
  doi = {10.1002/cbic.202500053}
}
Kostenlos starten →